Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study - J. A. Ledermann, B. Zurawski, F. Raspagliesi, U. De Giorgi, J. Arranz Arija, M. Romeo Marin, A. Lisyanskaya, R. L. Póka, J. Markowska, C. Cebotaru, A. Casado Herraez, N. Colombo, E. Kutarska, M. Hall, A. Jacobs - Dissemin

Language
Login

Published in

Esmo Open, Esmo Open, 1(7), p. 100311, 2022

DOI: 10.1016/j.esmoop.2021.100311

Links

Esmo Open

Tools

Export citation

Search in Google Scholar

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

Journal article published in 2022 by J. A. Ledermann, B. Zurawski, F. Raspagliesi, U. De Giorgi, J. Arranz Arija, M. Romeo Marin, A. Lisyanskaya, R. L. Póka, J. Markowska, C. Cebotaru, A. Casado Herraez, N. Colombo, E. Kutarska, M. Hall, A. Jacobs and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle

Preprint: policy unknown

Upload

Question mark in circle

Postprint: policy unknown

Upload

Question mark in circle

Published version: policy unknown

Upload

Policy details

Data provided by

SHERPA/RoMEO